Table 2.

Status of tetranucleotide marker defects, microsatellite instability, and hMSH3 expression in 40 EMAST-positive cancers

No	Diagnosis	Shape	MYCL1	D9S242	D20S85	D8S321	D20S82	MSI result	hMSH3 loss (%)
39	MD	Ulcerative	◯				◯	MSS	6
113	MD	Ulcerative	◯			◯		MSS	7
183	MD	Ulcerative	◯			◯		MSS	8
205	MD	Ulcerative			◯	◯		MSS	8
117	MD	Ulcerative	◯	◯				MSS	11
171	MD	Ulcerative	◯			◯		MSS	15
9	MD	Polypoid	◯	◯				MSS	18
75	MD	Ulcerative				◯	◯	MSS	27
165	MD	Ulcerative	◯	◯				MSS	30
181	MD	Ulcerative		◯		◯		MSS	32
187	MD	Ulcerative	◯			◯		MSS	33
175	PD	Ulcerative				◯	◯	MSS	38
11	MD	Ulcerative	◯			◯		MSS	60
15	MD	Ulcerative			◯	◯		MSS	94
65	MD	Ulcerative		◯			◯	MSS	95
23	MD	Sessile				◯	◯	MSS	95
55	MD	Ulcerative		◯			◯	MSS	99
153	MD	Ulcerative		◯		◯		MSS	99
121	MD	Ulcerative	◯				◯	MSS	99
107	MD	Ulcerative	◯		◯			MSS	99
89	MD	Ulcerative			◯	◯		MSI-L	2
207	MD	Ulcerative			◯	◯		MSI-L	61
77	PD	Ulcerative		◯		◯		MSI-L	62
61	MD	Ulcerative		◯	◯			MSI-L	100
7	WD	Sessile		◯	◯	◯		MSS	4
147	MD	Ulcerative		◯		◯	◯	MSS	10
57	MD	Polypoid			◯	◯	◯	MSS	14
47	MD	Ulcerative		◯	◯		◯	MSS	26
85	MD	Ulcerative		◯		◯	◯	MSS	29
93	MD	Ulcerative	◯			◯	◯	MSS	30
103	MD	Ulcerative	◯		◯		◯	MSS	59
115	MD	Ulcerative	◯		◯		◯	MSS	88
97	MD	Ulcerative	◯		◯		◯	MSS	89
33	MD	Polypoid		◯	◯		◯	MSS	98
71	MD	Ulcerative		◯		◯	◯	MSS	99
17	MD	Ulcerative	◯	◯		◯		MSI-L	51
53	MD	Ulcerative		◯		◯	◯	MSI-L	100
27	MD	Polypoid	◯	◯		◯	◯	MSI-L	94
41	MD	Ulcerative	◯	◯	◯		◯	MSS	98
141	MD	Ulcerative	◯	◯	◯	◯	◯	MSS	99

WD, well-differentiated adenocarcinoma; MD, moderately-differentiated adenocarcinoma; PD, poorly-differentiated adenocarcinoma; MSI-L, microsatellite instability-low; MSS, microsatellite stable. ◯ indicates tetranucleotide frameshift defect.